FDA advises drug companies to revise ADHD drug labeling

Share this content:

The FDA has directed manufacturers of all drug products approved for the treatment of attention deficit hyperactivity disorder (ADHD) to develop Patient Medication Guides to alert patients of possible cardiovascular risks and risks of adverse psychiatric symptoms associated with the medicines, and to advise them of precautions that can be taken.

For more information visit www.fda.gov/cder/drug/infopage/ADHD/default.htm.

You must be a registered member of Clinical Advisor to post a comment.

Next Article in News

2018 Upcoming Meetings

Sign Up for Free e-newsletters